CU24534B1 - Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3 - Google Patents
Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3Info
- Publication number
- CU24534B1 CU24534B1 CU2017000137A CU20170137A CU24534B1 CU 24534 B1 CU24534 B1 CU 24534B1 CU 2017000137 A CU2017000137 A CU 2017000137A CU 20170137 A CU20170137 A CU 20170137A CU 24534 B1 CU24534 B1 CU 24534B1
- Authority
- CU
- Cuba
- Prior art keywords
- ganglioside
- nano
- synthetic
- ceramide
- stimulated
- Prior art date
Links
- 239000002671 adjuvant Substances 0.000 title abstract 3
- -1 GM3 GANGLIOSIDE Chemical class 0.000 title 1
- PFJKOHUKELZMLE-VEUXDRLPSA-N ganglioside GM3 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(=O)CCCCCCCCCCCCC\C=C/CCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 PFJKOHUKELZMLE-VEUXDRLPSA-N 0.000 abstract 6
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 abstract 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 abstract 2
- 229940106189 ceramide Drugs 0.000 abstract 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 abstract 2
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 2
- 229930195729 fatty acid Natural products 0.000 abstract 2
- 239000000194 fatty acid Substances 0.000 abstract 2
- 150000004665 fatty acids Chemical class 0.000 abstract 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 abstract 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 abstract 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 abstract 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 abstract 1
- 102000001301 EGF receptor Human genes 0.000 abstract 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 1
- 241000588650 Neisseria meningitidis Species 0.000 abstract 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000005642 Oleic acid Substances 0.000 abstract 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 abstract 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 abstract 1
- 235000021355 Stearic acid Nutrition 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000028996 humoral immune response Effects 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 abstract 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 abstract 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 239000008117 stearic acid Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001144—Hormones, e.g. calcitonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
<p>Esta invención describe adyuvantes nano-particulados basados en diferentes variantes sintéticas del gangliósido GM3. Cuando el ácido graso presente en el ceramido del GM3 sintético es el ácido esteárico GM3 (18:0) se estimula una respuesta inmune específica de tipo humoral. En el caso de que sea el ácido oleico GM3 (18:1) el que se encuentre en el ceramido del GM3, la respuesta inmune específica que se estimula es de tipo celular. Particularmente, esta invención provee composiciones vacunales inmunogénicas que tienen como antígenos los receptores de factores de crecimiento HER1, HER2, HER3 solos o combinados o el péptido GnRHm1-TT y como adyuvantes nano-partículas formadas mediante la asociación del gangliósido GM3 formado por ácidos grasos totalmente sintéticos a proteínas hidrofóbicas del complejo de membrana externa de Ia bacteria Neisseria meningitidis.</p>
Priority Applications (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2017000137A CU24534B1 (es) | 2017-11-06 | 2017-11-06 | Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3 |
| NZ764565A NZ764565B2 (en) | 2018-10-24 | Nano-particles that contain synthetic variants of gm3 ganglioside as adjuvants in vaccines | |
| SG11202004180SA SG11202004180SA (en) | 2017-11-06 | 2018-10-24 | Nano-particles that contain synthetic variants of gm3 ganglioside as adjuvants in vaccines |
| CN201880071890.1A CN111295200A (zh) | 2017-11-06 | 2018-10-24 | 作为疫苗中的佐剂的包含合成的神经节苷脂gm3变体的纳米颗粒 |
| PCT/CU2018/050003 WO2019086056A1 (es) | 2017-11-06 | 2018-10-24 | Nano-partículas que contienen variantes sintéticas del gangliósido gm3 como adyuvantes en vacunas |
| JP2020525926A JP7332592B2 (ja) | 2017-11-06 | 2018-10-24 | ワクチンアジュバントとしての、ｇｍ３ガングリオシドの合成バリアントを含有するナノ粒子 |
| KR1020207016172A KR102728174B1 (ko) | 2017-11-06 | 2018-10-24 | 백신 보조제로서 gm3 강글리오시드의 합성 변이체를 포함하는 나노입자 |
| AU2018359358A AU2018359358B2 (en) | 2017-11-06 | 2018-10-24 | Nano-particles that contain synthetic variants of GM3 ganglioside as adjuvants in vaccines |
| BR112020008668-1A BR112020008668A2 (pt) | 2017-11-06 | 2018-10-24 | nanopartículas que contêm variantes sintéticas de gangliosídeo gm3 como adjuvantes em vacinas |
| EA202091116A EA202091116A1 (ru) | 2017-11-06 | 2018-10-24 | Наночастицы, содержащие синтетические варианты ганглиозида gm3, в качестве адъювантов в вакцинах |
| MX2020004644A MX2020004644A (es) | 2017-11-06 | 2018-10-24 | Nano-particulas que contienen variantes sinteticas del gangliosido gm3 como adyuvantes en vacunas. |
| EP18822259.0A EP3711775A1 (en) | 2017-11-06 | 2018-10-24 | Nano-particles that contain synthetic variants of gm3 ganglioside as adjuvants in vaccines |
| CA3079105A CA3079105A1 (en) | 2017-11-06 | 2018-10-24 | Nano-particles that contain synthetic variants of gm3 ganglioside as adjuvants in vaccines |
| US16/760,954 US11806396B2 (en) | 2017-11-06 | 2018-10-24 | Nano-particles that contain synthetic variants of GM3 ganglioside as adjuvants in vaccines |
| TW107137740A TWI719351B (zh) | 2017-11-06 | 2018-10-25 | 於疫苗中作為佐劑的包含ｇｍ３神經節苷脂的合成變體之奈米粒子 |
| ARP180103229A AR114139A1 (es) | 2017-11-06 | 2018-11-06 | Nano-partículas que contienen variantes sintéticas del gangliósido gm3 como adyuvantes en vacunas |
| CONC2020/0006548A CO2020006548A2 (es) | 2017-11-06 | 2020-05-28 | Nano-partículas que contienen variantes sintéticas del gangliósido gm3 como adyuvantes en vacunas |
| ZA2020/03218A ZA202003218B (en) | 2017-11-06 | 2020-05-29 | Nano-particles that contain synthetic variants of gm3 ganglioside as adjuvants in vaccines |
| US18/375,788 US20240131152A1 (en) | 2017-11-06 | 2023-10-02 | Nano-particles that contain synthetic variants of gm3 ganglioside as adjuvants in vaccines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2017000137A CU24534B1 (es) | 2017-11-06 | 2017-11-06 | Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20170137A7 CU20170137A7 (es) | 2019-06-04 |
| CU24534B1 true CU24534B1 (es) | 2021-07-02 |
Family
ID=64745822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2017000137A CU24534B1 (es) | 2017-11-06 | 2017-11-06 | Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11806396B2 (es) |
| EP (1) | EP3711775A1 (es) |
| JP (1) | JP7332592B2 (es) |
| CN (1) | CN111295200A (es) |
| AR (1) | AR114139A1 (es) |
| AU (1) | AU2018359358B2 (es) |
| BR (1) | BR112020008668A2 (es) |
| CA (1) | CA3079105A1 (es) |
| CO (1) | CO2020006548A2 (es) |
| CU (1) | CU24534B1 (es) |
| EA (1) | EA202091116A1 (es) |
| MX (1) | MX2020004644A (es) |
| SG (1) | SG11202004180SA (es) |
| TW (1) | TWI719351B (es) |
| WO (1) | WO2019086056A1 (es) |
| ZA (1) | ZA202003218B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU24534B1 (es) | 2017-11-06 | 2021-07-02 | Ct Inmunologia Molecular | Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3 |
| CU24637B1 (es) | 2019-12-24 | 2022-12-12 | Ct Ingenieria Genetica Biotecnologia | Polipéptidos que comprenden mutantes del vegf-a humano con re-arreglos de puentes disulfuro y composiciones que los contienen |
| CU24705B1 (es) | 2020-10-22 | 2024-06-11 | Ct Ingenieria Genetica Biotecnologia | Antígeno quimérico que comprende el dominio extracelular de pd-l1 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6149921A (en) * | 1993-12-29 | 2000-11-21 | Centro De Inmunologia Molecular | Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment |
| IS4518A (is) * | 1997-07-09 | 1999-01-10 | Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group | Nýtt lyfjaform fyrir bóluefni |
| PE20020572A1 (es) * | 2000-12-06 | 2002-07-31 | Centro Inmunologia Molecular | Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos |
| CU23257A1 (es) * | 2003-02-27 | 2008-01-24 | Centro Inmunologia Molecular | COMPOSICIONES VACUNALES A BASE DE GANGLIOSIDOS PARA LA ADMINISTRACION SUBCUTáNEA |
| US7776346B2 (en) | 2003-05-22 | 2010-08-17 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Personal product compositions comprising structured benefit agent premix or delivery vehicle |
| CU23739A1 (es) | 2008-09-30 | 2011-12-28 | Ct Ingenieria Genetica Biotech | Composición farmacéutica utilizando combinaciones de variantes de la hormona liberadora de las gonadotropinas (gnrh) como inmunógeno |
| US8343498B2 (en) * | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
| CU24299B1 (es) | 2013-08-02 | 2017-12-08 | Centro De Inmunología Molecular | Composiciones vacunales bivalentes basadas en los receptores de tipo 1 y 2 del factor de crecimiento epidérmico |
| CU24534B1 (es) | 2017-11-06 | 2021-07-02 | Ct Inmunologia Molecular | Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3 |
-
2017
- 2017-11-06 CU CU2017000137A patent/CU24534B1/es unknown
-
2018
- 2018-10-24 CN CN201880071890.1A patent/CN111295200A/zh active Pending
- 2018-10-24 EA EA202091116A patent/EA202091116A1/ru unknown
- 2018-10-24 BR BR112020008668-1A patent/BR112020008668A2/pt unknown
- 2018-10-24 MX MX2020004644A patent/MX2020004644A/es unknown
- 2018-10-24 EP EP18822259.0A patent/EP3711775A1/en active Pending
- 2018-10-24 WO PCT/CU2018/050003 patent/WO2019086056A1/es active Application Filing
- 2018-10-24 US US16/760,954 patent/US11806396B2/en active Active
- 2018-10-24 JP JP2020525926A patent/JP7332592B2/ja active Active
- 2018-10-24 SG SG11202004180SA patent/SG11202004180SA/en unknown
- 2018-10-24 CA CA3079105A patent/CA3079105A1/en active Pending
- 2018-10-24 AU AU2018359358A patent/AU2018359358B2/en active Active
- 2018-10-25 TW TW107137740A patent/TWI719351B/zh active
- 2018-11-06 AR ARP180103229A patent/AR114139A1/es unknown
-
2020
- 2020-05-28 CO CONC2020/0006548A patent/CO2020006548A2/es unknown
- 2020-05-29 ZA ZA2020/03218A patent/ZA202003218B/en unknown
-
2023
- 2023-10-02 US US18/375,788 patent/US20240131152A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018359358A1 (en) | 2020-06-11 |
| TW201927804A (zh) | 2019-07-16 |
| BR112020008668A2 (pt) | 2020-10-06 |
| NZ764565A (en) | 2024-02-23 |
| JP2021501792A (ja) | 2021-01-21 |
| ZA202003218B (en) | 2022-05-25 |
| SG11202004180SA (en) | 2020-06-29 |
| US11806396B2 (en) | 2023-11-07 |
| JP7332592B2 (ja) | 2023-08-23 |
| AU2018359358B2 (en) | 2022-08-04 |
| MX2020004644A (es) | 2020-07-24 |
| CU20170137A7 (es) | 2019-06-04 |
| KR20200086315A (ko) | 2020-07-16 |
| TWI719351B (zh) | 2021-02-21 |
| CO2020006548A2 (es) | 2020-08-21 |
| US20200268878A1 (en) | 2020-08-27 |
| EP3711775A1 (en) | 2020-09-23 |
| AR114139A1 (es) | 2020-07-29 |
| EA202091116A1 (ru) | 2020-09-24 |
| WO2019086056A1 (es) | 2019-05-09 |
| US20240131152A1 (en) | 2024-04-25 |
| CA3079105A1 (en) | 2019-05-09 |
| CN111295200A (zh) | 2020-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121789T1 (el) | Νεες ανοσοενισχυτικες συνθεσεις | |
| MX2024009845A (es) | Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm). | |
| CU24534B1 (es) | Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3 | |
| CR20180174A (es) | Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer | |
| EP3556353A3 (en) | Lipid nanoparticle vaccine adjuvants and antigen delivery systems | |
| ES2585328T3 (es) | Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis | |
| EA201691146A1 (ru) | Иммуногенное соединение | |
| BR112015012711A2 (pt) | método de produção de uma vacina de mycoplasma | |
| MX2013012219A (es) | Método de administración de vacunas. | |
| CU23576A1 (es) | Antígenos vacunales quiméricos contra el virus de la influenza aviar | |
| PH12015501716B1 (en) | Anti-mycoplasma spp. subunit vaccine | |
| EA201790558A1 (ru) | Композиция с пониженной иммуногенностью | |
| WO2017044803A8 (en) | Expression vector delivery system and use thereof for inducing an immune response | |
| AR099960A1 (es) | Procedimientos y composición farmaceutica para inducir una respuesta inmunitaria | |
| EA201692375A1 (ru) | Антитело-опосредованные вакцины и способы их применения для получения быстрых зрелых иммунных ответов | |
| PH12014501795B1 (en) | Rotavirus subunit vaccines and methods of making and use thereof | |
| EP4321218A3 (en) | Cancer stem cell targeted cancer vaccines | |
| CU24299B1 (es) | Composiciones vacunales bivalentes basadas en los receptores de tipo 1 y 2 del factor de crecimiento epidérmico | |
| BR112016012435A8 (pt) | vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2 | |
| CO6640312A2 (es) | Composiciones vacunales a base de sticholisina encapsulada en liposomas | |
| PL404229A1 (pl) | Wyizolowany immunogenny antygen bakteryjny i jego zastosowanie w profilaktyce i leczeniu zakażeń wywołanych przez Gram-ujemne bakterie | |
| BR112014001287A2 (pt) | vacina recombinante do vírus da leucemia felina contendo gene otimizado do envelope do vírus da leucemia felina | |
| MA40034A (fr) | Fabrication et utilisation d'ovotransferrine moderne (otf-m) | |
| NZ764565B2 (en) | Nano-particles that contain synthetic variants of gm3 ganglioside as adjuvants in vaccines | |
| BR112015011944A2 (pt) | preparação de vacinas vivas |